EUVIMEDEUVIMED entdecken
Open Access

Discovery and preclinical evaluation of monoclonal antibodies and bispecific engagers targeting the NKG2A inhibitory receptor

Seungmin Shin iD, Yae-Jin Kim iD, Bernard J C Macatangay iD, Joshua C Cyktor iD, Margaret G Hines, Ze-Yu Sun iD, Kong Chen, John W Mellors iD, Dimiter S Dimitrov iD, Wei Li iD, Du-San Baek iD

Science Advances · 2026

DOI: 10.1126/sciadv.adu0690 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Seungmin Shin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: NK Cell Lectin-Like Receptor Subfamily C, Antibodies, Monoclonal, Antibodies, Bispecific, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NK and T cells are key effectors that eliminate cancer cells, but upregulation of the inhibitory receptor NKG2A on these cells attenuates antitumor immune responses. To counteract NKG2A inhibitory signaling, we identified two specific fully human monoclonal anti-NKG2A antibodies that block HLA-E ligand binding. These antibodies activated NK cells and enhanced antibody-dependent cellular cytotoxicity of tumor-targeting IgG1s both in vitro and in vivo. Bispecific engagers (BiNKs), generated by fusing NKG2A antibodies with tumor targeting binders, promoted immune synapse formation and directed cytotoxicity of NK and CD8 + T cells toward cancer cells. In a human PBMC-engrafted NSG mouse xenograft lung cancer model, an anti-HER2 × anti-NKG2A BiNK markedly inhibited tumor growth as a monotherapy or in combination with pertuzumab. Cell depletion studies revealed that the BiNK enhanced antitumor activity of both NK and T cells. NKG2A blockade with potent and specific, fully human antibodies and BiNKs show promise for further development as cancer immunotherapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NK Cell Lectin-Like Receptor Subfamily CAntibodies, MonoclonalAntibodies, BispecificAntineoplastic Agents, ImmunologicalHumansAnimalsMiceKiller Cells, NaturalHLA-E AntigensCell Line, TumorXenograft Model Antitumor AssaysErb-b2 Receptor Tyrosine KinasesAntibody-Dependent Cell CytotoxicityCD8-Positive T-Lymphocytes

Substanzen

NK Cell Lectin-Like Receptor Subfamily CAntibodies, MonoclonalAntibodies, BispecificHLA-E AntigensKLRC1 protein, humanErb-b2 Receptor Tyrosine KinasesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • GLPG US, 1401 Forbes Avenue, Pittsburgh, PA, USA.
  • Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

ORCID-Profile: Seungmin Shin, Yae-Jin Kim, Bernard J C Macatangay, Joshua C Cyktor, Ze-Yu Sun, John W Mellors, Dimiter S Dimitrov, Wei Li, Du-San Baek

Förderung

  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Shin, S., Kim, Y. J., Macatangay, B. J. C., Cyktor, J. C., Hines, M. G., Sun, Z. Y., Chen, K., Mellors, J. W., Dimitrov, D. S., Li, W., & Baek, D. S. (2026). Discovery and preclinical evaluation of monoclonal antibodies and bispecific engagers targeting the NKG2A inhibitory receptor. Science Advances. https://doi.org/10.1126/sciadv.adu0690

Vancouver

Shin S, Kim YJ, Macatangay BJC, Cyktor JC, Hines MG, Sun ZY, et al. Discovery and preclinical evaluation of monoclonal antibodies and bispecific engagers targeting the NKG2A inhibitory receptor. Science Advances. 2026. doi:10.1126/sciadv.adu0690

BibTeX
@article{Shin2026,
  author = {Shin, Seungmin and Kim, Yae-Jin and Macatangay, Bernard J C and Cyktor, Joshua C and Hines, Margaret G and Sun, Ze-Yu and Chen, Kong and Mellors, John W and Dimitrov, Dimiter S and Li, Wei and Baek, Du-San},
  title = {Discovery and preclinical evaluation of monoclonal antibodies and bispecific engagers targeting the NKG2A inhibitory receptor},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.adu0690}
}
Kostenlos starten →